YOLFTbeta
Neovacs S.A.

Neovacs S.A.

ALNEV · PA · Healthcare / Biotechnology

0.0686EUR-0.01 (-10.44%)

Price History

Full chart

Market Stats

Previous Close0.0766
Open0.0766
Day Range0.0671 – 0.0789
52-Week Range0.18 – 2,200.00
Volume307.34K
Market Cap8
P/E (TTM)0.00
Forward P/E0.00
EPS-221.36
Dividend Yield0.00%
Beta-1252.22
50-Day Avg0.512
200-Day Avg12.37

About

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hugo Brugiere M.Sc.
  • Employees16
  • Headquarters14 Rue de la Republic FR, Suresnes, France, 92150, France
  • Websitehttps://www.neovacs.com

Leadership

  • Mr. Hugo Brugiere M.Sc.Chairman, GM & CEO
  • Prof. Daniel Zagury M.D., Ph.D.Founder, Chairman of Scientific Research Committee & Director
  • Mr. Vincent Serra Ph.D.Scientific & Operational Director · b. 1970
  • Mr. Alexandre CourtouxAdministrative & Financial Director
  • Charlene MassonCorporate Communication & Investor Relations
  • Mr. Bernard FangetVP of Pharmaceutical Affairs & Director

Financials

Income Statement

Currency: EUR2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue126.86K54.37K370.20K17.12K7.61M2029.87K141.82K147.89K15.43K12.83K145.00K95.15K29.78K22.59K1.11K533.41K366.35K161.78K
Growth (%)--57.14%+580.85%-95.37%+44321.39%-100.00%+149260.00%+374.77%+4.28%-89.57%-16.81%+1029.81%-34.38%-68.70%-24.14%-95.08%+47868.71%-31.32%-55.84%
Cost of Revenue475.94K371.38K298.31K9.98M10.53M8.28M7.87M9.75M1.58M2.71M58.41K9.50M56.21K3.42M7.62M6.26M7.29M323.93K4.69M
Gross Profit-349.08K-317.00K-298.31K-9.98M-10.53M-8.28M-7.84M-9.61M-1.43M-2.70M-58.41K-9.35M-56.21K-3.39M-7.60M-6.26M-6.75M42.42K-4.52M
Gross Margin-275.16%-583.02%-80.58%-58314.85%-138.39%-41380425.00%-26245.92%-6777.27%-965.41%-17494.81%-455.13%-6449.27%-59.07%-11388.40%-33620.50%-563037.68%-1266.26%11.58%-2796.53%
Operating Expense4.86M6.66M8.33M55.88K41.96K61.41K57.36K4.89K10.82M14.49M19.00M3.73M8.21M100.96K242.99K183.99K153.19K6.81M903.13K
Operating Income-5.21M-6.97M-8.62M-10.04M-10.57M-8.34M-7.90M-9.62M-12.25M-17.19M-19.06M-13.08M-8.27M-3.49M-7.84M-6.44M-6.91M-6.76M-5.43M
Operating Margin-4106.85%-12827.49%-2329.70%-58641.21%-138.94%-41687465.00%-26437.94%-6780.72%-8281.07%-111411.14%-148480.77%-9020.69%-8690.86%-11727.38%-34695.90%-579583.27%-1294.97%-1846.44%-3354.77%
EBITDA-5.13M-4.93M-8.28M-10.08M-9.54M-8.13M-7.82M-9.61M-7.14M-17.19M-18.29M-13.08M-9.14M-4.63M-10.38M-3.61M-8.45M-6.61M-5.24M
EBITDA Margin-4045.04%-9068.54%-2236.49%-58864.47%-125.48%-40641390.00%-26191.57%-6772.96%-4827.17%-111434.37%-142531.71%-9022.76%-9604.22%-15539.03%-45933.23%-324511.24%-1584.06%-1804.67%-3239.99%
Net Income-4.75M-4.63M-6.89M-8.98M-8.11M-7.15M-6.87M-7.51M-4.68M-13.93M-14.84M-10.78M-7.55M-6.14M-11.84M-3.55M-8.74M-32.91M-4.90M
Net Income Margin-3748.10%-8519.86%-1861.36%-52466.34%-106.68%-35750845.00%-22997.13%-5297.32%-3166.39%-90312.20%-115618.20%-7434.48%-7932.63%-20624.03%-52389.03%-319109.98%-1639.16%-8984.51%-3026.84%
R&D4.48M6.30M7.76M8.06M7.72M5.41M6.26M7.80M10.68M14.66M16.48M10.59M5.87M1.20M4.22M2.50M4.47M4.01M-
R&D as % of Total Revenue3534.58%11582.95%2097.26%47073.94%101.51%27045000.00%20968.91%5500.88%7223.60%95016.47%128370.38%7304.14%6166.00%4021.10%18679.21%224833.99%838.00%1094.32%-
Interest Expense160.18K69.62K105.90K172.90K108.28K131.16K149.78K163.10K68.81K99.46K509.31K473.00K106.89K2.00M2.00M586.08K1.01M20.40M937.89K
Interest Expense % of Total Revenue126.26%128.03%28.61%1009.81%1.42%655825.00%501.42%115.00%46.52%644.71%3968.41%326.21%112.33%6717.85%8853.12%52705.40%188.74%5567.37%579.73%

Balance Sheet

Currency: EUR2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.01M8.70M4.52M10.68M12.98M6.21M7.67M9.05M11.25M9.33M11.67M7.24M7.54M13.49M48.55M49.28M47.53M22.07M22.14M
Total Liabilities2.04M2.19M4.88M2.40M2.41M2.59M4.19M3.49M5.18M8.08M10.82M4.80M4.80M2.50M4.65M5.05M3.71M4.01M4.10M
Total Equity1.67M5.28M-1.61M6.08M7.89M941.43K386.28K2.47M6.07M1.26M845.75K2.44M2.74M10.98M43.90M44.23M43.82M18.06M18.03M
Cash2.21M6.28M4.46K307.19K215.10K158.25K3.22M5.17M5.38M3.76M5.15M1.42M1.30M10.07M16.25M43.08K887.09K435.44K571.78K
Total Debt1.06M959.20K3.96M718.06K865.73K975.26K1.12M1.29M741.93K808.66K2.45M65.46K64.37K391.83K1.03M1.20M650.59K230.37K537.20K
Net Debt-1.14M-5.32M3.95M410.87K650.64K817.02K-2.10M-3.88M-4.64M-2.95M-2.70M-1.35M-1.24M-9.69M-15.22M1.16M-236.50K-205.07K-34.58K

Cash Flow

Currency: EUR2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.32M-4.49M-7.95M-8.10M-8.63M-6.33M-7.00M-8.05M-7.69M-11.00M-14.26M-13.31M-8.10M-5.65M-9.91M-4.45M-1.91M-3.60M-5.03M
Investing Cash Flow-27.56K-51.88K-28.82K-306.62K-68.31K-34.15K-36.26K-3.11K-124.66K-574.16K-136.94K-30.95K42.49K-222.71K-18.81M-31.56M-11.08M1.45M-446.17K
Financing Cash Flow6.53M9.07M2.96M14.47M10.88M175.75K6.71M9.67M8.28M9.44M15.59M9.61M7.94M14.65M51.75M9.99M6.79M1.70M5.62M
Capital Expenditure25.67K27.05K28.82K84.56K68.31K4.12K34.64K25.16K19.19K114.57K130.09K10.05K2.35K206.95K348.86K152.75K203.40K79.71K6.21K
Free Cash Flow-4.34M-4.51M-7.98M-8.18M-8.70M-6.34M-7.04M-8.08M-7.71M-11.11M-14.39M-13.32M-8.10M-5.86M-10.26M-4.60M-2.12M-3.68M-5.04M
FCF to OCF100.59%100.60%100.36%101.04%100.79%100.07%100.49%100.31%100.25%101.04%100.91%100.08%100.03%103.66%103.52%103.43%110.63%102.21%100.12%

Earnings

Report DateMar 27, 2014Sep 17, 2014Mar 7, 2016Oct 11, 2016Apr 27, 2017Oct 27, 2017Apr 27, 2018Oct 30, 2018Sep 10, 2019Oct 2, 2019Nov 20, 2020Jun 29, 2021Oct 28, 2021May 2, 2022Oct 31, 2022Nov 4, 2024Apr 30, 2025Nov 21, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual0.000.000.00-0.16-0.16-0.15-0.08-0.06-0.04-0.03-0.022.280.00-5.95-0.200.000.00-5.11
Surprise------------------
Timing-Pre-marketAfter-hoursPre-market-After-hours-After-hours-After-hours--------

Key Statistics & Ratios

Market Cap8
Enterprise Value-124.10K
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.00
Price / Book0.00
EPS-221.36
Book Value39.63
Revenue (TTM)199.27K
Gross Profit (TTM)-2.91M
EBITDA-5.52M
Profit Margin0.00%
Operating Margin-1683.64%
Return on Equity-23.23%
Return on Assets-10.66%
Shares Outstanding47
Shares Float176.16M
Beta-1252.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 23, 20261:10000
  • Jul 18, 20251:1000
  • Dec 5, 20241:10000
  • Feb 2, 20241:10000
  • Jun 2, 20231:8000
  • Feb 1, 20221:10000
  • Jun 2, 2016441:428
  • Feb 19, 20131177:1143